GE HealthCare to Embark on a Collaboration to Elevate Women’s Imaging
Project aims to increase access of advanced imaging techniques for clinicians to help drive improved diagnosis and management of female...
Pharmaceutical
Real-world Evidence Solutions Market to be Worth $6.37 Billion by 2031–Exclusive Report by Meticulous Research®
REDDING, Calif., Aug. 19, 2024 /PRNewswire/ -- According to a new market research report titled, "Real-world Evidence Solutions Market Size, Share, Forecast,...
Falfurrias Management Partners Announces Investment in Jumo Health, An Innovative Clinical Trial Solutions Platform Driving Better Health Outcomes
CHARLOTTE, N.C., Aug. 19, 2024 /PRNewswire/ -- Falfurrias Management Partners (Falfurrias), a Charlotte-based private equity firm focused on growth-oriented, middle-market businesses, today announced...
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage...
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Asentech Named PM360 Trailblazer Award Finalist for App/Digital Solution Category
NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / PM360, a monthly magazine for marketing decision makers in...
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase...
Audax Private Equity to Acquire Avantor’s Clinical Services Business
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) announced today it has entered into a definitive agreement to acquire the...
Genmab Announces Changes to its Executive Committee
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed...
Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or...
Therma Bright’s AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial
Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a...
Sanyou Bio’s Innovative Intelligent Antibody Design oneClick+ Platform is Officially Launched
SHANGHAI, Aug. 15, 2024 /PRNewswire/ -- On August 16, 2024 (local time), Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch...
Policy Reporter by Mercalis Introduces Payer Compliance Dashboard
Tool helps Hospitals, Health Systems, and Physician Practices Address Financial Impact of Payer Denials MORRISVILLE, N.C., Aug. 15, 2024 /PRNewswire/...
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic...
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected...
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...